ATHA Stock Recent News

ATHA Energy Corp (TSX-V:SASK, OTCQB:SASKF) revealed that a survey at its Angilak uranium project in Nunavut has expanded the known depth of uranium mineralization at the Lac 50 Deposit to over one kilometer. The survey also identified a new 25-kilometer conductive trend along the western margin of the Angikuni Basin, according to a statement from ATHA.

Seattle-area biotech company Athira Pharma agreed to pay $4.

ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) announced that it has entered into option agreement with Terra Uranium Ltd (ASX:T92) which allow the two companies to earn significant interest in each other's uranium exploration projects. ATHA has granted Terra Uranium an option to acquire up to 70% interest in its Spire and Horizon properties, together the Spire Horizon projects.

ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) CEO Troy Boisjoli highlighted the company's aggressive growth strategy and plans for the year ahead in a discussion at the TD Securities Annual Nuclear Fuel Cycle and Next Generation Nuclear Roundtable. ATHA, listed in April 2023, has rapidly expanded its uranium exploration portfolio.

ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has expanded its Angilak Project in Nunavut by acquiring the entire Lac 50 structural corridor, along with an additional prospective parallel corridor. Both corridors are linked to the Snowbird Tectonic Zone, a significant crustal structure that extends from the Athabasca Basin to the Angikuni Basin.

Seattle-based biotech company Athira Pharma is laying off 49 people, or about 70% of its workforce, as part of cost-cutting measures and a restructuring.

Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.

On Wednesday, Athira Pharma, Inc. ATHA stock is trading lower after the company released topline results from its Phase 2/3 LIFT-AD clinical trial of fosgonimeton for mild-to-moderate Alzheimer's disease (AD).

Athira Pharma said on Tuesday its investigative drug failed to meet the main goal in a mid-to-late stage trial in patients with mild-to-moderate Alzheimer's disease.

ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) announced it has completed its 2024 Exploration Program at its Angilak uranium project in Nunavut, which hosts the Lac 50 uranium Deposit. The “highly successful” program was carried out from early June to late August and involved 25 diamond drill holes totalling about 10,051 meters.